# TILT-123

Source: https://onco.cc/drugs/tilt-123/  
OnCo record `tilt-123` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TILT-123 is an oncolytic virus from TILT Biotherapeutics Ltd., in registered phase 2 trials for ovarian cancer.

## Summary

TILT-123 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by TILT Biotherapeutics Ltd., in ovarian cancer. An oncolytic virus, as described in the registry record: a virus engineered to infect and burst tumour cells and alert the immune system. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123)
- Tags: pipeline; ctgov-ingest; registry-only
- Code: TILT-123
- Modality: Oncolytic virus
- Mechanism: An oncolytic virus, as described in the registry record: a virus engineered to infect and burst tumour cells and alert the immune system.

## Sources

- ClinicalTrials.gov: trials of TILT-123: https://clinicaltrials.gov/search?intr=TILT-123

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- trials: [Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) ](https://onco.cc/trials/nct05271318/)

---
JSON: https://onco.cc/api/v1/entities/tilt-123.json